Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...

Revelation Biosciences (REVB) announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells exposed ...

Therefore, exosomes represent a novel source of tumor-rejection antigens for T-cell cross priming, relevant for immunointerventions.